联合[177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T治疗的多同位素定量SPECT显像生物分布与剂量学
本研究纳入8例前列腺癌患者,在[177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T治疗后24小时行单床位定量SPECT/CT采集,以440 keV(213Bi子体)和208 keV(177Lu)双峰成像。结果显示肾脏和病灶的[177Lu]与[225Ac] SUV均呈强且显著相关;肾脏SUV在[225Ac]Ac-PSMA-I&T显著更高,病灶SUV在[177Lu]Lu-PSMA-I&T显著更高。作者结论认为低计数定量SPECT显像可行,多同位素显像提示肾脏中存在游离213Bi蓄积。
要点
- 8例前列腺癌患者接受1000 MBq [177Lu]Lu-PSMA-I&T/8 MBq [225Ac]Ac-PSMA-I&T治疗。
- 治疗后24小时单床位定量SPECT/CT采集,肾脏SUV相关系数r=0.96(p<0.01),病灶r=0.94(p<0.01)。
- 肾脏SUV在[225Ac]Ac-PSMA-I&T显著更高,病灶SUV在[177Lu]Lu-PSMA-I&T显著更高。
核心结论
- 在[225Ac]Ac-PSMA-I&T治疗期间对440 keV峰行定量低计数SPECT显像可行。
- 多同位素显像提示[177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T治疗中肾脏存在游离213Bi蓄积。
研究设计与样本
- 研究纳入8例前列腺癌患者,每例接受1000 MBq [177Lu]Lu-PSMA-I&T/8 MBq [225Ac]Ac-PSMA-I&T治疗。
- 治疗后24小时行单床位定量177Lu/225Ac SPECT/CT采集(1小时),使用高能准直器、每头16个投影、每个投影3.5分钟、128×128像素。
- 同时采集213Bi子体440 keV峰(宽度10%)与177Lu 208 keV峰(宽度15%)。
- 定量包括基于CT的衰减校正、基于窗的散射校正及分辨率建模。
- 分别采用全宽半高30 mm和40-45 mm的高斯后滤波以匹配225Ac和177Lu的信噪比。
主要发现
- 肾脏SUV在[177Lu]Lu-PSMA-I&T与[225Ac]Ac-PSMA-I&T之间呈强且显著相关(r=0.96,p<0.01)。
- 病灶SUV在[177Lu]Lu-PSMA-I&T与[225Ac]Ac-PSMA-I&T之间呈强且显著相关(r=0.94,p<0.01)。
- 肾脏SUV在[225Ac]Ac-PSMA-I&T显著高于[177Lu]Lu-PSMA-I&T(2.5±0.8 vs. 2.1±0.9,p<0.01)。
- 病灶SUV在[177Lu]Lu-PSMA-I&T显著高于[225Ac]Ac-PSMA-I&T(1.8±1.1 vs. 2.1±1.5,p=0.03)。
- 吸收剂量估算中肾脏的显著差异仍然存在,而病灶剂量学未见显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Quantitative SPECT for patient-specific dosimetry is a valuable tool in the scope of radionuclide therapy, although its clinical application for 225Ac-based treatments may be limited due to low therapeutic activities. Therefore, the aim of this study was to demonstrate the feasibility of clinical quantitative low-count SPECT imaging during [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T treatment. METHODS: Eight prostate cancer patients (1000 MBq/8 MBq [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T) received a single-bed quantitative 177Lu/225Ac SPECT/CT acquisition (1 h) at 24 h post treatment (high-energy collimator, 16 projections p. head à 3.5 min, 128 × 128 pixel). The gamma peak at 440 keV (width: 10%) of the progeny 213Bi was imaged along with the peak at 208 keV (width: 15%) of 177Lu. Quantification included CT-based attenuation and window-based scatter correction plus resolution modelling. Gaussian post-filtering with a full-width-half-maximum of 30 mm and 40-45 mm was employed to match the signal-to-noise ratio of 225Ac and 177Lu, respectively. RESULTS: Kidney (r = 0.96, p < 0.01) and lesion (r = 0.94, p < 0.01) SUV for [177Lu]Lu-PSMA-I&T and [225Ac]Ac-PSMA-I&T showed a strong and significant correlation. Kidney SUV were significantly higher (p < 0.01) for [225Ac]Ac-PSMA-I&T (2.5 ± 0.8 vs. 2.1 ± 0.9), while for [177Lu]Lu-PSMA-I&T lesion SUV were significantly higher (p = 0.03; 1.8 ± 1.1 vs. 2.1 ± 1.5). For absorbed dose estimates, significant differences regarding the kidneys remained, while no significant differences for lesion dosimetry were found. CONCLUSION: Quantitative low-count SPECT imaging of the peak at 440 keV during [225Ac]Ac-PSMA-I&T therapy is feasible. Multi-isotope imaging for [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy indicates accumulation of free 213Bi in the kidneys.
引用
- Delker A, Schleske M, Liubchenko G, et al. Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023. PMID: 36629878. doi:10.1007/s00259-022-06092-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。